현재 위치：홈 > 뉴스현황 > Our Events > Assisting the develo...
저자：medicilon 업로드：2022-10-28 조회수：
On October 19, AnDiCon Bio (AnDiCon) officially launched the phase II/III clinical study of ADC189 tablets, a new class 1 anti-influenza drug. The drug is expected to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China.
It is worth mentioning that ADC189 will also add new research on pediatric indications while starting the clinical phase II/III trial. Shanghai Medicilon Inc (Medicilon) is fortunate to undertake the formulation R&D of ADC189, helping the class 1 anti-influenza new drug ADC189 to benefit more patients.
ADC189 has launched clinical phase II/III, which is an important breakthrough in the field of anti-infection of the respiratory tract in China, and is also a testimony to the independent R&D strength of AnDiCon. Medicilon, which also focuses on innovation, has vigorously entered the CDMO field in recent years. Currently, Medicilon preparation CDMO can undertake the whole process of preparation R&D from project evaluation, pre-prescription research, preparation process research, quality research, clinical sample production, stability research and registration, which assist the R&D of innovative drugs. A number of innovative drugs have completed formulation development, which were successfully approved for clinical use, through Medicilon's high-end formulation technology platforms, such as inhalation drug research and development platform, ophthalmic drug research and development platform, and topical skin preparation research and development platform.
Led by a number of top domestic scientists and academicians, AnDiCon has an efficient and pragmatic project team with an international perspective. Relying on the platform advantages of the company's DMPK new drug discovery platform, AnDiCon is committed to solving the accessibility of innovative drugs in the field of respiratory anti-infection and gynecology in China. AnDiCon's product pipeline also includes urgently needed oral new drugs for endometriosis and uterine fibroids, 3CL protease inhibitory anti-COVID-19 drugs, and anti-RSV drugs. As a leading Biotech company in the field of respiratory anti-infection and gynecology, AnDiCon has been recognized by many well-known investment institutions.
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the mid 2022, Medicilon has provided new drug R&D services to more than 1,710 clients around the world, and participated in the R&D of 268 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.
